Recent work | April 4, 2022

Roschier represented Axcel in its divestment of Aidian to Nordstjernan

Funds managed by Axcel Management A/S have sold the Aidian group, a global provider of in vitro diagnostics instruments and tests, to Nordstjernan. Roschier represented Axcel in the transaction.

Nordic private equity firm Axcel acquired Aidian in 2018. Under Axcel’s ownership, Aidian has, among other things, strengthened its organization around the world, expanded its direct sales network, focused on research and development and launched new diagnostic tests. Furthermore, as a leading provider of COVID-19 diagnostic tests across Europe, Aidian continues to play an important role in the fight against COVID-19. As a result, Aidian has doubled its revenue in the last four years and significantly increased its margins.

Roschier’s main advisory team comprised Jon Unnérus, Valentin Golovanov, Laura Hakkarainen, Andreas Bussman, Mattias Brännkärr, Johanna Flythström, Mika Ohtonen and Johannes Ahti.